SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Nuvation Bio Inc. (NUVB) has a negative trailing P/E of -7.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 83.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -13.09%, forward earnings yield 1.20%. PEG 0.11 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.11); analyst target implies upside (+155.7%).
- Forward P/E 83.6 — analysts expect a return to profitability with estimated EPS of $0.06 for FY2029.
- PEG Ratio 0.11 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -13.09% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 1.20% as earnings recover.
- Analyst consensus target $12.40 (+155.7% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 55/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NUVB
Valuation Multiples
P/E (TTM)-7.6
Forward P/E83.6
PEG Ratio0.11
Forward PEG0.11
P/B Ratio5.11
P/S Ratio25.02
EV/EBITDA-7.3
Per Share Data
EPS (TTM)$-0.59
Forward EPS (Est.)$0.06
Book Value / Share$0.89
Revenue / Share$0.18
FCF / Share$-0.50
Yields & Fair Value
Earnings Yield-13.09%
Forward Earnings Yield1.20%
Dividend Yield0.00%
Analyst Target$12.40 (+155.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2018 |
-1,852.2 |
0.00 |
-2,469.57 |
0.00 |
- |
| 2019 |
-61.6 |
-0.02 |
17.55 |
0.00 |
- |
| 2020 |
-61.1 |
-3.26 |
11.84 |
0.00 |
- |
| 2021 |
-19.4 |
-0.15 |
2.25 |
0.00 |
- |
| 2022 |
-4.0 |
-0.44 |
0.64 |
0.00 |
- |
| 2023 |
-4.4 |
0.16 |
0.55 |
0.00 |
- |
| 2024 |
-1.3 |
0.00 |
1.54 |
90.81 |
- |
| 2025 |
-15.0 |
0.21 |
10.01 |
48.65 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-0.01 |
$0.00 |
$-992K |
- |
| 2019 |
$-0.16 |
$0.00 |
$-33.55M |
- |
| 2020 |
$-0.40 |
$0.00 |
$-41.66M |
- |
| 2021 |
$-0.44 |
$0.00 |
$-86.85M |
- |
| 2022 |
$-0.48 |
$0.00 |
$-104.2M |
- |
| 2023 |
$-0.35 |
$0.00 |
$-75.8M |
- |
| 2024 |
$-2.11 |
$7.87M |
$-567.94M |
-7213.8% |
| 2025 |
$-0.60 |
$62.9M |
$-204.63M |
-325.3% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.47 |
$-0.96 – $-0.25 |
$192.97M |
$189.46M – $199.65M |
5 |
| 2027 |
$-0.26 |
$-0.75 – $0.02 |
$295.41M |
$284.04M – $306.79M |
5 |
| 2028 |
$-0.12 |
$-0.31 – $0.31 |
$406.61M |
$354.36M – $465.42M |
6 |
| 2029 |
$0.04 |
$0.04 – $0.05 |
$513.82M |
$436.58M – $573.41M |
4 |
| 2030 |
$0.49 |
$0.41 – $0.58 |
$766.23M |
$582.52M – $765.08M |
2 |
